This past week brought a piece of news that is easy to welcome. There is talk of a proposed new fund to back British science, offering fresh long term backing to science and technology companies as they grow at home. The details will take time to settle, and none of it is her doing, yet the direction of travel is exactly the kind of thing Nicole Junkermann has hoped to see for years. Britain, she has always maintained, does not lack for brilliant science. What it has sometimes lacked is capital patient enough, and ambitious enough, to help that science grow into companies that stay.
The reason the story matters is not really the size of any figure. What matters is the intent behind it, which is to keep more of the value created by British research inside the country that created it. For a long time the pattern has run the other way. A discovery is made in a laboratory, a company forms around it, the company begins to show promise, and then, at the very moment it needs to grow, it finds that the next stage of support sits somewhere across an ocean. Too often it moves to find that support, and Britain keeps the credit while somewhere else keeps the company.
Where the science actually lives
It is no accident that the story of this proposed fund keeps returning to our university towns, because that is where so much of the science actually lives. Nicole Junkermann has written before about these places, and her admiration for them has only grown. They are not the loudest corners of the country. A visitor could walk through one on an August afternoon and see old stone, a river, a scatter of cafes and a great many bicycles, and never guess that the streets around them are producing ideas at a rate the largest cities would envy. A strong research institution gathers clever, restless people, teaches them, and then poses the interesting question of what they do next. In the towns that thrive, more and more of them choose to stay and build.
The pattern, once it begins, tends to compound. A finding in a laboratory becomes a small company in a nearby building. That company hires the next wave of graduates, some of whom leave a few years later to start something of their own. Investors who once needed persuading to visit begin to arrive of their own accord. The lawyers, accountants and recruiters who understand young companies set up close by, and each of them quietly lowers the cost of starting the next one. A town stops being a place people pass through on the way to somewhere bigger, and becomes a destination in its own right. This is slow work, and it is easy to underestimate precisely because it is slow.
Why patient money fits the moment
What a fund of this kind can do, if it is built with care, is shorten the journey at the point where it most often breaks. Nicole Junkermann has spent much of her career arguing for patient capital, by which she means money that is willing to wait, to hold through the long and unglamorous middle years of a company, and to judge progress against the mission rather than against the last quarter's figures. Science rewards exactly that temperament. The hard problems, in medicine, in clean energy, in computing and in materials, do not resolve themselves on a convenient timetable. They reward founders prepared to stay the course, and they reward backers prepared to stay with them.
There is a further reason to welcome an effort aimed beyond the capital. When serious companies can be founded and can grow in a modest town, and can stay there as they succeed, the benefits reach people and places that the older model never touched. Opportunity stops being the property of one crowded city and starts to belong to the whole country. Nicole Junkermann regards this as one of the healthiest possible shifts in an economy, not because it is fashionable, but because a nation that spreads its chances widely tends to be steadier, more inventive and more at ease with itself.
None of this is guaranteed by an announcement, and she would be the first to say so. A proposal is not a fund, and a fund is not a result. Money can be raised with good intentions and still be spent impatiently, chasing quick wins rather than backing the harder, slower work that actually lasts. The test will be whether this kind of capital behaves the way the science needs it to behave, staying close enough to notice a genuine change and far enough away not to react to every passing month. That is a discipline rather than a slogan, and it is learned only with practice.
Still, the mood behind the news is worth holding on to. Ask the people actually doing the building, the founders and researchers and the small teams working late in unremarkable offices, and lately you tend to hear less about difficulty and more about possibility. That change in tone usually arrives before the results do. Britain has the science, it has the talent, and it has, increasingly, the will to keep both at home. A serious pool of patient money, pointed at the towns where the ideas are born, would connect strengths that have for too long sat just out of reach of one another. For Nicole Junkermann, that is reason enough for a quiet, well founded optimism, and a good deal to look forward to as the summer turns towards autumn.
This article is general reflection and commentary. It is not financial or investment advice.
Visit the Nicole Junkermann homepage, read more about Nicole Junkermann, see the full biography of Nicole Junkermann, or return to the journal.
